Approval

Quote









Anonymous said:
Why do you say that? Where's your evidence?
Click to expand...

8-5 close vote by FDA last fall, 3 month delay in approval, REMS, compliance with injections, osteosarcoma risk and cost could scare endos. But most importantly, how NPS management has been spouting the market is 60,000 new patients per year. It's not, it's a smaller subset (see below.) Talk to top endos and H&N surgeons they'll tell you 12,000-15,000. If I'm a rep, I'd worry that Natpara goals are going to be more geared towards the 60,000 population than the 15,000. In other words, unrealistic sales quotas. NPS might have exaggerated this patient population to get sold. I'm not saying there isn't a market, but be careful, it's not as big as being touted. Below is what you need to look at very closely as far as "well controlled" patients on calcium and vitamin D. That's the vast majority of hypoparathyroid patients:

"Because of the potential risk of osteosarcoma, Natpara is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. Natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations or in patients with acute post-surgical hypoparathyroidism."
 


Anonymous said:
8-5 close vote by FDA last fall, 3 month delay in approval, REMS, compliance with injections, osteosarcoma risk and cost could scare endos. But most importantly, how NPS management has been spouting the market is 60,000 new patients per year. It's not, it's a smaller subset (see below.) Talk to top endos and H&N surgeons they'll tell you 12,000-15,000. If I'm a rep, I'd worry that Natpara goals are going to be more geared towards the 60,000 population than the 15,000. In other words, unrealistic sales quotas. NPS might have exaggerated this patient population to get sold. I'm not saying there isn't a market, but be careful, it's not as big as being touted. Below is what you need to look at very closely as far as "well controlled" patients on calcium and vitamin D. That's the vast majority of hypoparathyroid patients:

"Because of the potential risk of osteosarcoma, Natpara is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. Natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations or in patients with acute post-surgical hypoparathyroidism."
Click to expand...

Funny cause none of that is evidence that it almost didn't get approved.
 


Anonymous said:
8-5 close vote by FDA last fall, 3 month delay in approval, REMS, compliance with injections, osteosarcoma risk and cost could scare endos. But most importantly, how NPS management has been spouting the market is 60,000 new patients per year. It's not, it's a smaller subset (see below.) Talk to top endos and H&N surgeons they'll tell you 12,000-15,000. If I'm a rep, I'd worry that Natpara goals are going to be more geared towards the 60,000 population than the 15,000. In other words, unrealistic sales quotas. NPS might have exaggerated this patient population to get sold. I'm not saying there isn't a market, but be careful, it's not as big as being touted. Below is what you need to look at very closely as far as "well controlled" patients on calcium and vitamin D. That's the vast majority of hypoparathyroid patients:

"Because of the potential risk of osteosarcoma, Natpara is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. Natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations or in patients with acute post-surgical hypoparathyroidism."
Click to expand...


Manager here. These are all moot points. Layoffs will be announced soon for both the Natpara and Gattex salesforce.
 






With shire buying NPS I am sure all hiring is on hold. Shire is all about cost cutting right now to stay "lean and mean" to get better price to sell the company and people like the CEO can make a fortune. Wake up people its all about money and not about people.
 


Anonymous said:
With shire buying NPS I am sure all hiring is on hold. Shire is all about cost cutting right now to stay "lean and mean" to get better price to sell the company and people like the CEO can make a fortune. Wake up people its all about money and not about people.
Click to expand...

Not true. Nps was told to fill all vacant sales positions.
 




We are filling open territories anyone who says anything different does not know what they are talking about. Prior poster is a troll looking to scare people. Focus on your job. Anything is out of our control anyway....
 





Write your reply...
Top Bottom
Back
Quote